Navigation Links
Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Date:2/7/2008

- Presentation to Be Webcast Live on Company's Website -

TUSTIN, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today announced that senior management will present at the 10th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2008 at 9:30 am EST. The conference will be held at the Waldorf-Astoria Hotel in New York City.

Paul J. Lytle, Peregrine's chief financial officer, will provide a review of recent corporate developments.

A live webcast and archived replay of the company's presentation will be available at the Investor Relations section of Peregrine's website at http://www.peregrineinc.com.

For more information about this conference, please visit: http://ceo.bio.org/opencms/ceo/2008/index.jsp

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
2. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
3. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
6. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
7. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
10. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017  GlobeImmune, Inc. today announced it has entered ... 12,835,490 shares of its common stock to NantCell, Inc., ... with the sale of its common stock, NantCell has ... to GlobeImmune 200,000 shares, an estimated $2.0 million in ... are pleased to enter into this strategic agreement with ...
(Date:3/23/2017)... 23, 2017 NetworkNewsWire Editorial Coverage  ... Cancer remains ... strain on health care systems, in terms of costs and ... too does the development of innovative and efficient therapies that ... the many types of cancer treatments, a growing number of ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice ... applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned ...
(Date:3/22/2017)... 22, 2017  UBM and the Massachusetts Medical ... extended partnership and the third annual Massachusetts Medtech Week. ... 21 st Annual MassMEDIC Conference held in ... 3-4, 2017. MassMEDIC will feature ... President and CEO, Scott Whitaker , at ...
Breaking Biology Technology:
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or against ... (PRNewsFoto/Dermalog Identification Systems) ... Matching" is the fastest software for biometric Face Matching on the market. The ...
(Date:3/6/2017)... Calif. , March 6, 2017 ... and sales technology, today announced Predictive Sales Coach ... for infusing actionable sales intelligence into Salesforce. This ... automatically enable their sales organizations with deep knowledge ... that allow for intelligent engagement. Predictive Sales Coach ...
Breaking Biology News(10 mins):